Each year, more than half a million people worldwide receive a diagnosis of hepatocellular carcinoma, and hepatocellular carcinoma related to HCV is the fastest rising cause of U.S. cancer-related deaths. This review summarizes recent advances in prevention, surveillance, diagnosis, and treatment.
Continue reading this article
Select an option below:
Create your account to get 2 free subscriber-only articles each month.
Dr. El-Serag reports receiving consulting fees from Vertex Pharmaceuticals and support from a grant from Bayer Pharmaceuticals to the Baylor College of Medicine.
Disclosure forms provided by the author are available at NEJM.org.
No other potential conflict of interest relevant to this article was reported.
Author Affiliations
From the Section of Gastroenterology and Hepatology, Michael E. DeBakey Veterans Affairs Medical Center; Baylor College of Medicine; and the Houston Center for Quality of Care and Utilization Studies — all in Houston.
Address reprint requests to Dr. El-Serag at the Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd. (152), Houston, TX 77030, or at [email protected].